EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive-variant prostate cancerMaryam Latarani(The Open University), Francesco Crea(The Open University)bioRxiv (Cold Spring Harbor Laboratory)September 11, 202410.1101/2024.09.06.611612Cited by 1SaveCiteExport RISWatch citationsRelated PapersIdentification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer|Clinical Epigenetics|2016|78EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines|Epigenomics|2025|4